A phase I/II study of recombinant interferon alpha 2a and hydroxyurea for chronic myelocytic leukemia
Author:
Publisher
Springer Science and Business Media LLC
Subject
Hematology,General Medicine,Hematology
Link
http://link.springer.com/content/pdf/10.1007/BF00320165.pdf
Reference10 articles.
1. Alimena G, Morra E, Lazzarino M, Liberati AM, Montefusco E, Inverardi D, Bernasconi P, Mancini M, Donti E, Grignani F, Bernasconi C, Dianzani F, Mandelli F (1988) Interferon alpha-2b as therapy for Ph-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration. Blood 72: 642?647
2. Anger BR, Carbonell F, Braunger I, Heinze B, Gutensohn W, Thiel E, Heimpel H (1988) Blast crisis of Philadelphia chromosome-positive chronic myelocytic leukemia (CML). Blut 57: 131?137
3. Bolin RW, Robinson WA, Sutherland J, Hamman RF (1982) Busulfan versus hydroxyurea in long-term therapy of chronic myelogenous leukemia. Cancer 50: 1683?1687
4. Hehlmann R, Anger BR, Messerer D, Zankovitch R, Bergmann L, Kolb HJ, Meyer P, Essers U, Queisser U, Vaupel H, Walter F, Hossfeld DK, Zimmermann R, Heiss F, Mende S, Tigges FJ, Kleeberg UR, Pralle H, Kayser W, Tichelli A, Faulhaber JD, Raeth U, Schubert H, Bross K, Schlag R, Schmidt L, Weissenfels I, Heinze B, Georgii A, Queisser W, Heimpel H (1988) Randomized study on the treatment of chronic myeloid leukemia (CML) in chronic phase with busulfan versus hydroxyurea versus interferon-alpha. Blut 56: 87?91
5. Kurzrock R, Talpaz M, Kantarijan H et al. (1987) Therapy of chronic myelogenous leukemia with recombinant interferon-gamma. Blood 70: 943?947
Cited by 28 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy?;Journal of Cancer Research and Clinical Oncology;2017-06-17
2. Trial Watch—Immunostimulation with cytokines in cancer therapy;OncoImmunology;2015-12-08
3. Trial watch;OncoImmunology;2014-06
4. What Is the Future of Immunotherapy in Ovarian Cancer?;Controversies in the Management of Gynecological Cancers;2013-10-16
5. Possibility to Partly Win the War Against Cancer;Recent Advances in Cancer Research and Therapy;2012
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3